The Efficacy of Fycompa (Perampanel) in Children With Epilepsy

Completed

• Conditions: Neurologic Disorder

• Registration Number: NCT04608799
• Lead Sponsor: National Taiwan University Hospital

Brief Summary

Fycompa (Perampanel), a new anti-epileptic drug that uses a new mechanism-AMPA receptor antagonist. Its initial indication is for local or generalized epilepsy in children and adults over 12 years old, but its effectiveness in the treatment of epilepsy in children At present, more evidence is still needed. We will study the effectiveness of Fycompa (Perampanel) in the treatment of epilepsy in children under the age of 18. It is expected that the clinical use of Fycompa (Parampanel) in Taiwan will be able to analyze and study the effectiveness of the clinical use of Fycompa (Parampanel) in the treatment of epilepsy in children, and compare it with foreign reports.

Detailed Description

Not available

Study Timeline

• Study Start: 2018-01-01
• Primary Completion: 2020-03-19
• Study Completion: 2020-03-19
• Status Verified: 2020-10
• Study First Submitted: 2020-10-20
• Study First Submitted QC: 2020-10-28
• Last Update Submitted: 2020-10-28
• Study First Posted: 2020-10-29
• Last Update Posted: 2020-10-29

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 38

Inclusion Criteria

• Patients under 18 years of age suffering from epilepsy
• Patients who are taking Paraampanel

Exclusion Criteria

• Patients who are not in the above age groups and who are not using parampanel

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The efficacy of perampanel in young children with drug-resistant epilepsy	17 years	Because the current clinical research data on the use of Fycompa (perampanel) in children for the treatment of epilepsy is still insufficient, the purpose of this research is to review the efficacy of this drug in the treatment of children with epilepsy in our hospital in the past, so as to facilitate the future clinical treatment of children with epilepsy. Children have the possibility of therapeutic reference.

Trial Locations

Locations (1)

National Taiwan University Hospital; 🇨🇳 Taipei, Taiwan